These participants showed A1C reductions of 2.02% alongside the blood pressure and lipid improvements, representing comprehensive cardiovascular risk modification
HS (7th author): Funding acquisition, Writing review & editing, Supervision
Selective small molecule agonists have been developed to activate many of these receptors, notably G protein-coupled receptor 40 (GPR40 [free fatty acid receptor (FFAR) 1]), GPR119 and GPR120 (FFAR4), and several have shown efficacy in animal models
It is not known if Ozempic will harm your unborn baby
Retatrutide is currently in Phase 3 clinical trials through the TRIUMPH program conducted by Eli Lilly
Eligibility was tightly controlled: as is customary across incretin research, people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome were excluded, and participants were monitored throughout